Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VEE DNA Vaccine via Jet Injection in Healthy Adults
NCT06002503Phase 1Active, not recruiting
- Sponsor
- PharmaJet
- Start
- Oct 2023
- Primary completion
- May 2025
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of Venezuelan equine encephalitis virus DNA vaccine in Venezuelan equine encephalitis (VEE) (4 arms), sponsored by PharmaJet. Primary endpoints: Number of participants with immediate reactions, Solicited adverse events and 2 more. Started Oct 2023; status: active, not recruiting.
02
Drugs
Venezuelan equine encephalitis virus DNA vaccine
03
Conditions
Venezuelan equine encephalitis (VEE)
Beyond the preview
Go deeper on NCT06002503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06002503.